EyePoint announced the launch of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation after cataract surgery. This marks the first long-acting intraocular steroid approved for the treatment of post-op inflammation.
Dexycu, administered as a single injection at the end of ocular surgery, is intended to replace the use of steroid eye drops. The product utilizes the Company’s Verisome sustained-release drug delivery technology to deliver a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye.
Dexycu was evaluated in a randomized, double-masked, placebo-controlled trial that assessed the proportion of patients with anterior chamber cell clearing (i.e., cell score=0) on postoperative day 8 (primary endpoint). Compared with placebo, a greater percentage of patients treated with Dexycu had anterior chamber clearing at Day 8 (20% in the placebo group vs 57% in the Dexycu 342mcg group and 60% in the Dexycu 517mcg group).
“Dexycu offers a single-dose, sustained release treatment option conveniently administered at the end of cataract surgery which can eliminate the complicated and burdensome steroid eye drop regimen following surgery,” stated Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.
Dexycu is available as a 9% suspension (equivalent to dexamethasone 103.4mg/mL) in a single-dose vial as part of a kit.
For more information call (833) 393-7646 or visit Dexycu.com.
This article originally appeared on MPR